ARCT Quote, Financials, Valuation and Earnings

Capricor Therapeutics has a net margin of -142.88% compared to Arcturus Therapeutics Holdings's net margin of -63.94%. Arcturus Therapeutics Holdings's return on equity of -31.04% beat Capricor Therapeutics's return on equity of -75.99%.

Arcturus Therapeutics Holdings has a consensus price target of $73.10, signalling upside risk potential of 467.55%. On the other hand Capricor Therapeutics has an analysts' consensus of $43.71 which suggests that it could grow by 239.93%. Given that Arcturus Therapeutics Holdings has higher upside potential than Capricor Therapeutics, analysts believe Arcturus Therapeutics Holdings is more attractive than Capricor Therapeutics.

Arcturus Therapeutics Holdings has a beta of 2.962, which suggesting that the stock is 196.207% more volatile than S&P 500. In comparison Capricor Therapeutics has a beta of 4.096, suggesting its more volatile than the S&P 500 by 309.586%.

Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Capricor Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. Capricor Therapeutics pays out -- of its earnings as a dividend.

Arcturus Therapeutics Holdings quarterly revenues are $21M, which are larger than Capricor Therapeutics quarterly revenues of $11.1M. Arcturus Therapeutics Holdings's net income of -$30M is lower than Capricor Therapeutics's net income of -$7.1M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while Capricor Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 2.51x versus 20.33x for Capricor Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -142.88% compared to Arcturus Therapeutics Holdings's net margin of -16566.39%. Arcturus Therapeutics Holdings's return on equity of -31.04% beat Inovio Pharmaceuticals's return on equity of -119.02%.

Arcturus Therapeutics Holdings has a consensus price target of $73.10, signalling upside risk potential of 467.55%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.83 which suggests that it could grow by 307.99%. Given that Arcturus Therapeutics Holdings has higher upside potential than Inovio Pharmaceuticals, analysts believe Arcturus Therapeutics Holdings is more attractive than Inovio Pharmaceuticals.

Arcturus Therapeutics Holdings has a beta of 2.962, which suggesting that the stock is 196.207% more volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.256%.

Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Arcturus Therapeutics Holdings quarterly revenues are $21M, which are larger than Inovio Pharmaceuticals quarterly revenues of $117K. Arcturus Therapeutics Holdings's net income of -$30M is lower than Inovio Pharmaceuticals's net income of -$19.4M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 2.51x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of -142.88% compared to Arcturus Therapeutics Holdings's net margin of -91.76%. Arcturus Therapeutics Holdings's return on equity of -31.04% beat Novavax's return on equity of --.

Arcturus Therapeutics Holdings has a consensus price target of $73.10, signalling upside risk potential of 467.55%. On the other hand Novavax has an analysts' consensus of $16.43 which suggests that it could grow by 115.88%. Given that Arcturus Therapeutics Holdings has higher upside potential than Novavax, analysts believe Arcturus Therapeutics Holdings is more attractive than Novavax.

Arcturus Therapeutics Holdings has a beta of 2.962, which suggesting that the stock is 196.207% more volatile than S&P 500. In comparison Novavax has a beta of 2.916, suggesting its more volatile than the S&P 500 by 191.569%.

Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

Arcturus Therapeutics Holdings quarterly revenues are $21M, which are smaller than Novavax quarterly revenues of $88.3M. Arcturus Therapeutics Holdings's net income of -$30M is higher than Novavax's net income of -$81M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 2.51x versus 1.75x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Sangamo Therapeutics has a net margin of -142.88% compared to Arcturus Therapeutics Holdings's net margin of -309.84%. Arcturus Therapeutics Holdings's return on equity of -31.04% beat Sangamo Therapeutics's return on equity of -217.48%.

Arcturus Therapeutics Holdings has a consensus price target of $73.10, signalling upside risk potential of 467.55%. On the other hand Sangamo Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 476.97%. Given that Sangamo Therapeutics has higher upside potential than Arcturus Therapeutics Holdings, analysts believe Sangamo Therapeutics is more attractive than Arcturus Therapeutics Holdings.

Arcturus Therapeutics Holdings has a beta of 2.962, which suggesting that the stock is 196.207% more volatile than S&P 500. In comparison Sangamo Therapeutics has a beta of 1.494, suggesting its more volatile than the S&P 500 by 49.44%.

Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sangamo Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. Sangamo Therapeutics pays out -- of its earnings as a dividend.

Arcturus Therapeutics Holdings quarterly revenues are $21M, which are larger than Sangamo Therapeutics quarterly revenues of $7.6M. Arcturus Therapeutics Holdings's net income of -$30M is lower than Sangamo Therapeutics's net income of -$23.4M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while Sangamo Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 2.51x versus 3.03x for Sangamo Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.